Furiex Pharmaceuticals, Inc.·4

Dec 7, 4:32 PM ET

Furiex Pharmaceuticals, Inc. 4

4 · Furiex Pharmaceuticals, Inc. · Filed Dec 7, 2011

Insider Transaction Report

Form 4
Period: 2011-12-05
COVINGTON PAUL S
Senior VP-Clinical Operations
Transactions
  • Purchase

    Common Stock

    2011-12-05$17.68/sh+2,850$50,3882,923 total
Holdings
  • Stock Options (to buy)

    Exercise: $9.11Exp: 2020-06-17Common Stock (75,691 underlying)
    75,691
  • Stock Options (to buy)

    Exercise: $13.16Exp: 2021-10-03Common Stock (37,944 underlying)
    37,944
  • Stock Options (to buy)

    Exercise: $15.00Exp: 2021-05-09Common Stock (26,000 underlying)
    26,000
Footnotes (4)
  • [F1]This transaction was executed in multiple trades at prices ranging from $17.75 to $17.98. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
  • [F2]The options were awarded on 6/17/2010 and vest over three years, with one-third vesting on each of the first, second and third anniversaries of the date of grant, provided the Optionee's employment continues.
  • [F3]The options were awarded on 5/9/2011. One-third of the options vest on the date of grant and the remaining two-thirds vest in two equal annual installments on the first and second anniversaries of the date of grant, provided the Optionee's employment continues.
  • [F4]The options were awarded on 10/3/2011 and vest over three years, with one-third vesting on each of the first, second and third anniversaries of the date of grant, provided the Optionee's employment continues.

Documents

1 file
  • 4
    rrd327350.xmlPrimary

    FORM 4